Home / What Cancers We Test For
CANCERS WE TEST FOR

Every cancer has a story. Let’s understand more of it.

Explore genomic testing for solid tumors and hematologic neoplasms—from common cancers to complex and rare diseases.

FIND YOUR WAYSolid tumorsHematologic neoplasmsBiomarker guideGuidelinesTesting optionsFAQs
A MORE COMPLETE VIEW

Different cancers. Different questions.

Cancer biology varies from person to person. Molecular profiling can provide information that helps the care team characterize disease, assess prognosis and consider treatment options in the right clinical context.

Testing is selected by a healthcare professional based on diagnosis, clinical question and available specimen. A molecular test does not detect every cancer or guarantee a treatment match.

DISEASE-BY-DISEASE REFERENCE

Cancer types, biomarkers and testing options.

Use this guide to explore examples of relevant biomarkers and GTC test families. The applicable markers and testing approach depend on diagnosis, subtype, stage, specimen and clinical question.

Solid tumor types and biomarker examples
Cancer type / examplesBiomarkers to considerGTC test families
LungNon-small cell and small cell lung cancersEGFR · ALK · ROS1 · BRAF · KRAS · MET exon 14 skipping · RET · NTRK · ERBB2 / HER2 · PD-L1Solid Tumor Profile Plus
Liquid Trace® Solid Tumor
BreastDuctal, lobular and triple-negative breast cancersER / PR · HER2 · ESR1 · PIK3CA · AKT1 · PTEN · BRCA1/2 · PD-L1Solid Tumor Profile Plus
Liquid Trace® Solid Tumor
ColorectalColon and rectal adenocarcinomaKRAS / NRAS · BRAF · MSI / MMR · HER2 · NTRK fusionsSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Gastric & esophagealGastric, gastroesophageal junction and esophageal cancersHER2 · PD-L1 · MSI / MMR · CLDN18.2Solid Tumor Profile Plus
Liquid Trace® Solid Tumor
Pancreatic & biliaryPancreatic adenocarcinoma, cholangiocarcinoma and gallbladder cancerKRAS · BRCA1/2 · PALB2 · MSI / MMR · NTRK · FGFR2 fusions / IDH1 in relevant biliary tumorsSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Ovarian & endometrialOvarian, fallopian tube, primary peritoneal and endometrial cancersBRCA1/2 · HRD · MSI / MMR · HER2 · FOLR1 / FRαSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
ProstateProstate adenocarcinoma and other prostate tumorsBRCA1/2 and other HRR genes · MSI / MMR · selected RNA alterationsSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Bladder & urothelialBladder and other urothelial carcinomasFGFR2/3 alterations · PD-L1 · HER2 · MSI / MMRSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Melanoma & skinCutaneous melanoma and other skin cancersBRAF · KIT · NRAS · tumor mutation burdenSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Brain & central nervous systemPrimary brain tumors and CNS involvement by cancerIDH1/2 · selected fusions and alterations · MGMT promoter methylation when clinically appropriateSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Sarcoma & GISTSoft tissue and bone sarcomas; gastrointestinal stromal tumorsKIT · PDGFRA · NTRK and other disease-associated fusionsSolid Tumor Profile Plus
Liquid Trace® Solid Tumor
Other & rare tumorsThyroid, head and neck, neuroendocrine, kidney and unknown primaryTumor-specific mutations and fusions · MSI / MMR · TMB when appropriateSolid Tumor Profile Plus
Liquid Trace® Solid Tumor

Marker examples are not a complete guideline list or a promise that every marker is reported by every profile. ER, PR, HER2, PD-L1, FOLR1 and CLDN18.2 can require IHC or other methods; MMR may be assessed by IHC, and MGMT methylation requires a separate assay. Confirm GTC assay scope, companion diagnostic status, availability and specimen requirements.

Hematologic neoplasms

Hematologic diseases and biomarker examples
DiseaseBiomarkers to considerGTC test families
Acute myeloid leukemia (AML)NPM1 · FLT3 · IDH1/2 · TP53 · KMT2A and other fusion partnersHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
Acute lymphoblastic leukemia (ALL)BCR::ABL1 · KMT2A rearrangements · other recurrent fusion transcriptsHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
Chronic lymphocytic leukemia (CLL)TP53 · IGHV mutation status · additional disease-associated alterationsHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
Chronic myeloid leukemia (CML)BCR::ABL1 and kinase-domain mutations as clinically indicatedHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
LymphomaB- and T-cell clonality · fusion transcripts · gene expression · chromosomal alterationsHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
Multiple myelomaFusions · chromosomal changes · gene expression · clonality · mutationsHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
MDS / CMMLTP53 · SF3B1 · ASXL1 · TET2 · other myeloid-associated genesHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
Myeloproliferative neoplasmsJAK2 · CALR · MPL · additional myeloid mutationsHematology Profile Plus
Hematology Profile
Liquid Trace® Hematology
VEXAS syndromeAutoinflammatory condition; not a cancerSomatic UBA1 variants · interpret alongside clinical findings and hematologic evaluationHematology Profile
Hematology Profile Plus
Liquid Trace® Hematology

RNA-based fusion, expression and clonality testing is profile-dependent. BCR::ABL1 quantitative monitoring and other disease-specific tests may require a separate method; check the individual assay before ordering.

GUIDELINES & CLINICAL CONTEXT

Use current guidance for each clinical question.

Biomarker recommendations vary by cancer type, disease stage, prior therapy and the intended treatment. Consult the current NCCN Clinical Practice Guidelines in Oncology and applicable therapy labels when selecting tests and interpreting results.

NCCN Guidelines®

The disease tables above are an educational starting point, not a reproduction of NCCN recommendations. Review the current disease-specific guideline and version for the patient’s setting.

Access NCCN Guidelines ↗

What has changed?

Recent FDA updates underscore the evolving role of biomarkers such as ESR1 in advanced breast cancer, KRAS G12C in colorectal cancer, and CLDN18.2 in gastric and GEJ cancer.

Explore FDA oncology approvals ↗

The NCCN guideline versions and exact testing recommendations have not yet been independently confirmed for this draft. GTC clinical review is needed before publication.

SOLID TUMORS

Explore solid tumor types.

From lung and breast cancer to rare tumors, GTC offers tissue and liquid biopsy profiling to support a range of clinical questions.

Lung & thoracic

Non-small cell and small cell lung cancers; mesothelioma and thymic tumors.

Breast

Ductal and lobular cancers, including triple-negative disease.

Gastrointestinal

Colorectal, gastric, esophageal, pancreatic, liver, bile duct and other gastrointestinal cancers.

Gynecologic

Ovarian, fallopian tube, endometrial, cervical and related cancers.

Genitourinary

Prostate, bladder and other urothelial cancers, and kidney cancers.

Head, neck & thyroid

Head and neck tumors and thyroid cancers.

Skin & melanoma

Melanoma, squamous and basal cell cancers, Merkel cell carcinoma and other skin tumors.

Sarcoma & GIST

Soft tissue and bone sarcomas, including gastrointestinal stromal tumors.

Brain & CNS

Primary brain tumors and cancers involving the central nervous system.

Other & rare tumors

Neuroendocrine tumors, cancer of unknown primary and other uncommon tumors.

HEMATOLOGIC NEOPLASMS

A closer look at blood cancers.

Explore molecular testing across myeloid, lymphoid and plasma cell diseases, with DNA and RNA options tailored to the clinical question.

Conceptual illustration of leukemia cells
MYELOID & LYMPHOID

Leukemia

From acute leukemias to CLL and CML, molecular findings can help characterize disease and inform care.

Explore testing options ↗
Conceptual illustration of lymphoma cells
B-CELL · T-CELL · HODGKIN

Lymphoma

Mutations, fusions, gene expression and clonality can provide complementary perspectives on lymphoid disease.

Explore testing options ↗
Conceptual illustration of plasma cells
PLASMA CELL NEOPLASMS

Multiple myeloma

DNA and RNA profiling can contribute to characterization and risk assessment alongside the full workup.

Explore testing options ↗

Illustrations are conceptual, not diagnostic images.

More hematologic conditions

Leukemia

Acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), chronic lymphocytic (CLL) and other leukemias.

Lymphoma

B-cell, T-cell and Hodgkin lymphomas, including cutaneous lymphomas.

Plasma cell neoplasms

Multiple myeloma and related plasma cell disorders.

MDS & MDS/MPN

Myelodysplastic neoplasms and overlapping disorders, including CMML.

Myeloproliferative neoplasms

Conditions including polycythemia vera, essential thrombocythemia and myelofibrosis.

VEXAS syndrome

VEXAS is an adult-onset autoinflammatory syndrome associated with acquired UBA1 variants. It can involve blood abnormalities and may coexist with MDS. It is not itself a cancer. GTC’s hematology profiles include UBA1 analysis to support evaluation in the appropriate clinical context.

Other hematologic neoplasms

Additional myeloid and lymphoid conditions; contact GTC for case-specific test selection.

TESTING OPTIONS

Match the profile to the question.

Our portfolio brings together tissue, bone marrow and liquid biopsy options. Availability depends on the test and specimen.

TISSUE · SOLID TUMORS

Solid Tumor Profile Plus

DNA and RNA profiling for molecular alterations, fusions and expression.

View profile ↗
MARROW · BLOOD · TISSUE

Hematology Profile Plus

DNA and RNA profiling for a broad range of hematologic neoplasms.

View profile ↗
BLOOD · CSF

Liquid Trace®

Cell-free DNA and RNA profiling for solid tumor and hematology applications.

Explore Liquid Trace ↗
QUESTIONS & ANSWERS

Frequently asked questions

Does GTC test for my cancer type?

GTC offers profiling across a broad range of solid tumors and hematologic neoplasms. The appropriate test depends on the disease, clinical question and specimen; contact client services for guidance.

Can liquid biopsy replace a tissue biopsy?

Liquid biopsy and tissue testing provide different information. The treating clinician determines which approach is appropriate, and tissue testing may still be needed.

Does a molecular test guarantee a treatment match?

No. Results may inform options, but not every finding has a matching therapy. The care team interprets findings alongside the full clinical picture.

How do patients get testing?

Talk with your treating clinician, who can determine whether testing is appropriate and arrange an order.

Have a question about a case?

Our client services team can help you explore testing and specimen options.

Contact client services ↗